{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:18:32Z","timestamp":1788884312163,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA034086-03"],"award-info":[{"award-number":["R01DA034086-03"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA023021"],"award-info":[{"award-number":["R25DA023021"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12954-017-0192-8","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T14:35:08Z","timestamp":1506695708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Perceived benefits of the hepatitis C peer educators: a qualitative investigation"],"prefix":"10.1186","volume":"14","author":[{"given":"A. W.","family":"Batchelder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cockerham-Colas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Peyser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Reynoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Soloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"issue":"5","key":"192_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/hep.27978","volume":"62","author":"BR Edlin","year":"2015","unstructured":"Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353\u201363.","journal-title":"Hepatology"},{"key":"192_CR2","unstructured":"Centers for Disease Control and Prevention. Available at: \n                    http:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm\n                    \n                  . Accessed 20 Sept 2017."},{"issue":"1","key":"192_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1300\/J069v20n01_03","volume":"20","author":"JJ McCarthy","year":"2001","unstructured":"McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis. 2001;20(1):19\u201331.","journal-title":"J Addict Dis"},{"issue":"3","key":"192_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0376-8716(00)00144-7","volume":"61","author":"MD Stein","year":"2001","unstructured":"Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001;61(3):211\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"25","key":"192_CR5","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405\u201316.","journal-title":"N Engl J Med"},{"issue":"9956","key":"192_CR6","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756\u201365.","journal-title":"Lancet"},{"issue":"1","key":"192_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.drugalcdep.2010.01.009","volume":"109","author":"B Schulte","year":"2010","unstructured":"Schulte B, Sch\u00fctt S, Brack J, et al. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend. 2010;109(1):248\u201351.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"192_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jsat.2008.09.009","volume":"37","author":"AH Litwin","year":"2009","unstructured":"Litwin AH, Harris KA, Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abus Treat. 2009;37(1):32\u201340.","journal-title":"J Subst Abus Treat"},{"issue":"5 Suppl 1","key":"192_CR9","first-page":"S3","volume":"36","author":"NIO Health","year":"2002","unstructured":"Health NIO. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002\u2014June 10\u201312, 2002. Hepatology (Baltimore, Md). 2002;36(5 Suppl 1):S3.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"10","key":"192_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.drugpo.2015.05.002","volume":"26","author":"JP Meyer","year":"2015","unstructured":"Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. International Journal of Drug Policy. 2015;26(10):922\u201335.","journal-title":"International Journal of Drug Policy."},{"issue":"4","key":"192_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1086\/600304","volume":"49","author":"M Hellard","year":"2009","unstructured":"Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49(4):561\u201373.","journal-title":"Clin Infect Dis"},{"issue":"Supplement 5","key":"192_CR12","doi-asserted-by":"publisher","first-page":"S304","DOI":"10.1086\/427445","volume":"40","author":"SA Strathdee","year":"2005","unstructured":"Strathdee SA, Latka M, Campbell J, et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005;40(Supplement 5):S304\u201312.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"192_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","volume":"33","author":"SH Mehta","year":"2008","unstructured":"Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126\u201333.","journal-title":"J Community Health"},{"issue":"11","key":"192_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.drugpo.2015.05.007","volume":"26","author":"D Wolfe","year":"2015","unstructured":"Wolfe D, Luhmann N, Harris M, et al. Human rights and access to hepatitis C treatment for people who inject drugs. International Journal of Drug Policy. 2015;26(11):1072\u201380.","journal-title":"International Journal of Drug Policy."},{"issue":"Supplement 5","key":"192_CR15","doi-asserted-by":"publisher","first-page":"S276","DOI":"10.1086\/427441","volume":"40","author":"BR Edlin","year":"2005","unstructured":"Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40(Supplement 5):S276\u201385.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"192_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJM200107193450311","volume":"345","author":"BR Edlin","year":"2001","unstructured":"Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345(3):211.","journal-title":"N Engl J Med"},{"issue":"3","key":"192_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJM200107193450312","volume":"345","author":"GL Davis","year":"2001","unstructured":"Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med. 2001;345(3):215\u20137.","journal-title":"N Engl J Med"},{"issue":"10","key":"192_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/jvh.12095","volume":"20","author":"E Chen","year":"2013","unstructured":"Chen E, North C, Fatunde O, et al. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV\/HIV co-infected adults. J Viral Hepat. 2013;20(10):708\u201314.","journal-title":"J Viral Hepat"},{"issue":"1","key":"192_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugpo.2007.02.003","volume":"19","author":"CE Munoz-Plaza","year":"2008","unstructured":"Munoz-Plaza CE, Strauss S, Astone-Twerell J, et al. Exploring drug users\u2019 attitudes and decisions regarding hepatitis C (HCV) treatment in the US. International Journal of Drug Policy. 2008;19(1):71\u20138.","journal-title":"International Journal of Drug Policy."},{"issue":"4","key":"192_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1006\/jado.1999.0248","volume":"22","author":"M Shiner","year":"1999","unstructured":"Shiner M. Defining peer education. J Adolesc. 1999;22(4):555\u201366.","journal-title":"J Adolesc"},{"issue":"3","key":"192_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1939-0025.2011.01103.x","volume":"81","author":"JM Simoni","year":"2011","unstructured":"Simoni JM, Franks JC, Lehavot K, Yard SS. Peer interventions to promote health: conceptual considerations. Am J Orthopsychiatry. 2011;81(3):351.","journal-title":"Am J Orthopsychiatry"},{"issue":"8","key":"192_CR22","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s10461-011-9963-5","volume":"15","author":"JM Simoni","year":"2011","unstructured":"Simoni JM, Nelson KM, Franks JC, Yard SS, Lehavot K. Are peer interventions for HIV efficacious? A systematic review. AIDS Behav. 2011;15(8):1589\u201395.","journal-title":"AIDS Behav"},{"issue":"10","key":"192_CR23","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.drugpo.2015.01.005","volume":"26","author":"C Treloar","year":"2015","unstructured":"Treloar C, Rance J, Bath N, et al. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: the ETHOS study, Australia. International Journal of Drug Policy. 2015;26(10):992\u20138.","journal-title":"International Journal of Drug Policy"},{"key":"192_CR24","unstructured":"Rance J, Treloar C. Integrating treatment: key findings from a qualitative evaluation of the Enhancing Treatment of Hepatitis C in Opiate Substitution Settings (ETHOS) study: National Centre in HIV Social Research; 2012. \n                    https:\/\/csrh.arts.unsw.edu.au\/media\/CSRHFile\/2_Integrating_treatment.pdf\n                    \n                  ."},{"issue":"1","key":"192_CR25","first-page":"42","volume":"113","author":"RS Broadhead","year":"1998","unstructured":"Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL, Madray H, Mills RJ, Hughes J. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Rep. 1998;113(1):42\u201357.","journal-title":"Public Health Rep"},{"issue":"Suppl 1","key":"192_CR26","first-page":"31","volume":"113","author":"LB Cottler","year":"1998","unstructured":"Cottler LB, Compton WM, Abdallah AB, et al. Peer-delivered interventions reduce HIV risk behaviors among out-of-treatment drug abusers. Public Health Rep. 1998;113(Suppl 1):31.","journal-title":"Public Health Rep"},{"issue":"2","key":"192_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0277-9536(01)00167-8","volume":"55","author":"RS Broadhead","year":"2002","unstructured":"Broadhead RS, Heckathorn DD, Altice FL, et al. Increasing drug users\u2019 adherence to HIV treatment: results of a peer-driven intervention feasibility study. Soc Sci Med. 2002;55(2):235\u201346.","journal-title":"Soc Sci Med"},{"issue":"14","key":"192_CR28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1097\/QAD.0b013e32823f9066","volume":"21","author":"RS Garfein","year":"2007","unstructured":"Garfein RS, Golub ET, Greenberg AE, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007;21(14):1923\u201332.","journal-title":"AIDS"},{"issue":"3","key":"192_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1521\/aeap.2009.21.3.181","volume":"21","author":"A Medley","year":"2009","unstructured":"Medley A, Kennedy C, O\u2019Reilly K, Sweat M. Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis. AIDS education and prevention: official publication of the International Society for AIDS Education. 2009;21(3):181.","journal-title":"AIDS education and prevention: official publication of the International Society for AIDS Education"},{"issue":"6","key":"192_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.drugpo.2013.05.018","volume":"24","author":"S Woolhouse","year":"2013","unstructured":"Woolhouse S, Cooper E, Pickard A. \u201cIt gives me a sense of belonging\u201d: providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group. International Journal of Drug Policy. 2013;24(6):550\u20137.","journal-title":"International Journal of Drug Policy."},{"issue":"10","key":"192_CR31","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.drugpo.2015.04.012","volume":"26","author":"K Mason","year":"2015","unstructured":"Mason K, Dodd Z, Sockalingam S, et al. Beyond viral response: a prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support. International Journal of Drug Policy. 2015;26(10):1007\u201313.","journal-title":"International Journal of Drug Policy"},{"key":"192_CR32","doi-asserted-by":"crossref","unstructured":"Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis. 2005;40(Supplement 5):S339-S45.","DOI":"10.1086\/427450"},{"issue":"2","key":"192_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1353\/hpu.2014.0096","volume":"25","author":"RJ Roose","year":"2014","unstructured":"Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. J Health Care Poor Underserved. 2014;25(2):652\u201362.","journal-title":"J Health Care Poor Underserved"},{"key":"192_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101.","journal-title":"Qual Res Psychol."},{"issue":"10","key":"192_CR35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.drugpo.2015.07.006","volume":"26","author":"J Keats","year":"2015","unstructured":"Keats J, Micallef M, Grebely J, et al. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. International Journal of Drug Policy. 2015;26(10):999\u20131006.","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"192_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/add.12392","volume":"109","author":"J Rance","year":"2014","unstructured":"Rance J, Treloar C. \u2018Not just methadone Tracy\u2019: transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. Addiction. 2014;109(3):452\u20139.","journal-title":"Addiction"},{"issue":"2","key":"192_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/10615808808248222","volume":"1","author":"A Bandura","year":"1988","unstructured":"Bandura A. Self-efficacy conception of anxiety. Anxiety research. 1988;1(2):77\u201398.","journal-title":"Anxiety research"},{"key":"192_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1477-7517-5-8","volume":"5","author":"J Norman","year":"2008","unstructured":"Norman J, Walsh N, Mugavin J, Stoov\u00e9 M, Kelsall J, Austin K, Lintzeris N. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduction Journal. 2008;5:8.","journal-title":"Harm Reduction Journal"},{"issue":"4","key":"192_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jsat.2012.08.007","volume":"43","author":"MR Stein","year":"2012","unstructured":"Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abus Treat. 2012;43(4):424\u201332.","journal-title":"J Subst Abus Treat"},{"key":"192_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.drugalcdep.2015.06.007","volume":"153","author":"A Batchelder","year":"2015","unstructured":"Batchelder A, Peyser D, Nahvi S, Arnsten J, Litwin A. \u201cHepatitis C treatment turned me around:\u201d psychological and behavioral transformation related to hepatitis C treatment. Drug Alcohol Depend. 2015;153:66\u201371.","journal-title":"Drug Alcohol Depend"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-017-0192-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-017-0192-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-017-0192-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T07:05:01Z","timestamp":1589526301000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-017-0192-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1186\/s12954-017-0192-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]},"assertion":[{"value":"9 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was approved by the Albert Einstein College of Medicine\u2019s Institutional Review Board, and all participants completed informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants completed informed consent, which included a description of publishing de-identified components of the transcribed interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"67"}}